集成的微/纳米药物递送系统,基于磁性响应的相变滴子,用于超声波治疗
Jieying Chen1, Chan Zhao2, Hao Liu1
1Department of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China.
Frontiers in bioengineering and biotechnology
|April 26, 2024
概括
研究人员开发了装有抗瘤药物的智能磁性纳米粒子. 这些相变滴提供先进的成像和向药物输送,显示癌症治疗的希望.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 相变滴 (PCD) 是响应的微/纳米材料,利用核心物质的相变,如 perfluorocarbons.
- PCD对外部刺激表现出智能反应,改变用于成像和药物输送的应用的特性.
研究的目的:
- 开发新的磁性药物载荷变相液滴,用于神经应用.
- 为了研究这些工程纳米滴的成像能力和药物释放特性.
主要方法:
- 基于脂质的相变液滴是使用 perfluorohexane (PFH) 作为核心来制备的.
- 超偏磁纳米粒子 (PEG功能化Fe3O4) 和黄素 (Cur) 被纳入脂质外,形成Fe-Cur-NDs.
- 在低强度聚焦超声波 (LIFU) 指导下,使用MCF-7细胞评估了体外抗瘤疗效.
主要成果:
- 合成的Fe-Cur-NDs显示出有效的磁共振/超声波成像特性.
- 通过热和超声调解实现了受控的药物释放.
- 在LIFU指导下,在体外观察到针对MCF-7细胞的显著抗瘤疗效.
结论:
- Fe-Cur-NDs代表了一个有前途的综合治疗系统,用于智能响应药物递送.
- 这种纳米滴系统为先进的癌症治疗策略提供了潜力.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.


